Worth reading
—
Scored from 0 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
110
¥ millionWording
Definitive
How definitive the wording is.Dividend per share
Total dividendsTotal amount payable to all shareholdersKRW 1,000 million (¥110 million)
| Item | Details |
|---|---|
| Total dividends | Not disclosed → KRW 1,000 million (¥110 million) |
Items this document does not state (11)
Dividend per shareTotal Annual DividendsPrevious-period results (per share)Record dateEffective dateSource of dividendsBreakdown of Regular, Commemorative and Special DividendsPayout ratioDividend policyWhether Submission to the General Meeting of Shareholders Is RequiredFiscal Period Covered
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.A dividend was received from LINICAL KOREA CO., LTD., a consolidated subsidiary. The dividend received will be recognized as non-operating income in the non-consolidated financial statements for the fiscal year ending March 2027, but the Company explains that it will have no impact on consolidated results because it is a dividend from a consolidated subsidiary.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.